Atea Pharmaceuticals, Inc. — Director's Dealing 2023

Feb 3, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2023-01-31

Reporting Person: Horga Maria Arantxa (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-31	Restricted Stock Units	$	A	124600	Acquired		Common Stock (124600)	Direct
2023-01-31	Stock Option (Right to Buy)	$4.63	A	174500	Acquired	2033-01-30	Common Stock (174500)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026.

F3: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2023 such that the option is fully vested on January 31, 2027.